IQV vs. RGEN: IQVIA vs. Repligen Stock Comparison
How do IQVIA (IQV) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
IQVIA (IQV) and Repligen (RGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | IQV | RGEN |
|---|---|---|
| Name | IQVIA Holdings Inc. | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 44.80 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 9, 2013 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | IQV | RGEN |
|---|---|---|
| Total Return (1Y) | 32.11% | 23.28% |
| Total Return (3Y, Annualized) | 13.15% | 6.20% |
| Total Return (5Y, Annualized) | 2.00% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | IQV | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 40.77% | 46.73% |
| Beta (5Y) | 1.14 | 1.11 |
| Max Drawdown (5Y) | -51.52% | -64.67% |
| Avg. Volume (3M) | 1.40M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | IQV | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.68 | 0.41 |
| Sortino Ratio (1Y) | 1.03 | 0.60 |
Profitability
ROE (TTM)
Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile IQVIA (IQV) reports 21.39%, ranking against industry peers normally.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.39%
- Max
- 109.18%
- IQV
- 21.39%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile IQVIA (IQV) reports 8.05%, ranking against industry peers normally.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.05%
- Max
- 18.05%
- IQV
- 8.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both IQVIA (IQV) at 13.73% and Repligen (RGEN) at 6.19% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.73%
- Max
- 83.12%
- Q3
- 14.77%
- IQV
- 13.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | IQV | RGEN |
|---|---|---|
| ROE (TTM) | 21.39% | -0.57% |
| ROA (TTM) | 5.08% | 1.40% |
| Net Margin (TTM) | 8.05% | -1.47% |
| Operating Margin (TTM) | 13.73% | 6.19% |
| Gross Margin (TTM) | 33.07% | 53.77% |
Growth
Revenue Growth
Both IQVIA (IQV) at 5.87% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: IQVIA (IQV) reports EPS growth of 4.67%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.
Growth Metrics
| Metric | IQV | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 5.87% | 16.36% |
| Revenue Growth (3Y CAGR) | 4.21% | -2.70% |
| EPS Growth (YoY) | 4.67% | -- |
| EPS Growth (3Y CAGR) | 11.08% | -35.73% |
Financial Strength
Current Ratio (MRQ)
Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while IQVIA (IQV) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for IQV.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- IQV
- 0.83
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Repligen (RGEN) at 0.33 is near its industry mid-range for debt-to-equity ratio, while IQVIA (IQV) at 2.40 sits above its benchmark range, pointing to a heavier debt load relative to equity.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.40
- IQV
- 2.40
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | IQV | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 9.88 |
| Debt / Equity (MRQ) | 2.40 | 0.33 |
| Net Debt / EBITDA | 4.46 | -1.19 |
Dividends
Dividend Yield (TTM)
Neither IQVIA (IQV) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- IQV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither IQVIA (IQV) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- IQV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | IQV | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: IQVIA (IQV) trades at 33.07 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.07
- Max
- 85.34
- Q3
- 43.46
- IQV
- 33.07
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Repligen (RGEN) at 13.77 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.59
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- IQV
- 2.59
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Repligen (RGEN) at 4.70 is valued about in line with its industry on P/B ratio, while IQVIA (IQV) at 6.73 carries an above-peer premium to book — IQV is pricier on assets.
IQV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.73
- Max
- 13.53
- IQV
- 6.73
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | IQV | RGEN |
|---|---|---|
| P/E Ratio (TTM) | 33.07 | -- |
| P/S Ratio (TTM) | 2.59 | 13.77 |
| P/B Ratio (MRQ) | 6.73 | 4.70 |
| Free Cash Flow Yield (TTM) | 4.72% | 1.01% |